TP53 (Tumor protein P53)

Its protective antioxidant effects in normal cells and anticancer effect make it a promising candidate for preventing the progression of HCC. The online version contains supplementary material available at 10.1007/s10616-026-00963-3.

The sequential multibiomarker algorithm achieved 96.5% sensitivity and 98.7% specificity for malignant PE detection, with 85.3% overall three-way classification accuracy. Multiomics integration combining proteomic biomarkers with single-cell immune profiling and genomic mutation characterization achieves high diagnostic accuracy for pleural effusion while revealing disease-specific immune mechanisms and mutation-driven therapeutic opportunities.

Additionally, copy number variations (CNVs) were evaluated, identifying chromosomal losses (e.g., Y chromosome, 1p12, 9p21.2-p21.3) and gains (e.g., 1q21.3, 6p22.3). This study establishes a foundational dataset for Bangladeshi bladder cancer patients, paving the way for further validation experiments in vitro, and the possibility of developing population-specific molecular biomarker panels, these insights may also contribute to personalized treatment strategies and help combat rising morbidity and recurrence rates of bladder cancer in Bangladesh.

We report a 69-year-old man with resectable stage IIB right upper lobe lung adenocarcinoma who received neoadjuvant pembrolizumab, carboplatin, and pemetrexed followed by robotic-assisted lobectomy. He received adjuvant pembrolizumab and daratumumab-CyBorD with partial hematologic response. This case highlighted that amyloid can unexpectedly be a second diagnosis after post-neoadjuvant lung resections and that proteomic subtyping is essential for prompt haematologic staging and treatment.

And neutrophils were exclusively observed within the tumor microenvironment (TME) of BMS. All these findings emphasized EALs' value in revolutionizing clinical decision-making for personalized treatment strategies in BRCA cases.

<br><br><b></b> This study delineated the mutational spectrum of recurrent and/or metastatic SDC. Even in advanced disease, prognostically relevant mutations were identified, emphasizing the clinical importance of cancer genomic profiling tests.

This work lays the basis for precision and personalised treatment for TNBC patients. However, future optimisation and clinical validation of these nanoparticles can be done in future to determine their translational potential for use in practice.

This study underscores the profoundly immunosuppressive microenvironment in gallbladder cancer originating from the neck/cystic duct (GBCN/CD), highlights the role of LAMB3+ tumor cells in immune modulation, and identifies LAMB3 as a potential therapeutic target for GBCN/CD.

P2, N=20, Not yet recruiting, Zhejiang Cancer Hospital

P1, N=18, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China